ct-2584 and Sarcoma

CT-2584, an anticancer agent that inhibits phospholipid signaling, is under development by Cell Therapeutics Inc (CTI) as a potential treatment for various types of cancer. Phase II trials are underway for the treatment of prostate cancer and soft-tissue sarcoma [306617], [324290]. According to CIBC World Markets, completion of enrolment for these trials was expected in the fourth quarter of 2000. Furthermore, the initiation of phase II/III trials in combination with taxotere for the treatment of prostate cancer was anticipated in the second half of 2000, as were phase I/II trials in combination with cisplatin for the treatment of other cancers, including lung cancer [396582]. Results of a phase II study in patients with soft-tissue sarcomas evaluating pharmacokinetics, tolerance and therapeutic activity were presented at the 2000 American Society of Clinical Oncology (ASCO) meeting [367283]. Further data are expected to be presented at the ASCO meeting in May 2001 [396582]. Cell Therapeutics is seeking development and commercialization partners for CT-2584 [386398].

Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drugs, Investigational; Enzyme Inhibitors; Fatigue; Hematuria; Humans; Male; Molecular Structure; Phosphatidic Acids; Phosphatidylcholines; Phospholipase D; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Xanthines

Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Male; Prostatic Neoplasms; Sarcoma; Xanthines